Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg—IL PSO (Italian Landscape Psoriasis)
Sign Up to like & getrecommendations! Published in 2025 at "Dermatology and Therapy"
DOI: 10.1007/s13555-025-01416-z
Abstract: Tildrakizumab is a monoclonal antibody targeting interleukin (IL)-23 approved for the treatment of moderate-to-severe plaque psoriasis across two different dosages (100 mg and 200 mg). The higher dosage is recommended for patients with a body… read more here.
Keywords: week multicenter; 100 200; multicenter retrospective; retrospective study ... See more keywords